Ukrainian Firm To Receive mRNA Tech Transfer From WHO Hub
The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.
You may also be interested in...
More than 200 people took part in a meeting to assess progress with an mRNA technology transfer program that is intended to give manufacturers in lower-income countries the ability to produce and sell their own vaccines for COVID-19 and other diseases.
An EU expert group and a number of member state agencies have published advice on the practicalities of safely moving Ukrainian clinical trial subjects to sites in EU and European Economic Area countries.
Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.